🧪 Our Biomed Bet

Plus: Bitcoin breaks a new record!

March 15, 2024

Good Morning!

We’re breaking down our positions and the news behind them.

Today, we're eyeballing Bitcoin's staggering surge past $73,000, dissecting market movers like Tesla, Nvidia, and more. Plus, dive into our hot pick, Psyence Biomed, riding high on groundbreaking research and our expert analyst Mr. M's bullish signal. It’s already up +6% since our call!

Let’s get into it 👇

🌡 Market Temperature Check

📈 Stock Catalyst

Psyence Biomed's Breakthrough

The Play:

Our analyst, Mr. M, has dropped another golden nugget in our TradingLab community. We’re talking about $PBM – Psyence Biomedical Ltd. A swing trade idea that's as hot as they come.

  • Entry Point: $1.65, right at the break.

  • Upside Levels: Look for climbs to $1.7, $1.75, $1.8, $1.9, and then soaring past $2.

And guess what? Shortly after Mr. M spilled the beans, $PBM did us a solid by hitting $1.75 – that’s a sweet +6% gain. But hold your horses; we’re not fully out yet. Our eyes are locked on that $2+ target.

The Catalyst:

So, what’s firing up $PBM? Psyence Biomedical just got a big thumbs-up from the Australian Health Research Ethics Committee (HREC). They’re all set to kickstart their Phase IIb study in Melbourne, Australia. This isn’t just any study; they’re diving into the world of nature-derived psilocybin, aiming to treat Adjustment Disorder for cancer diagnosis patients in palliative care. This groundbreaking work is being helmed by their subsidiary, Psyence Australia.

Approval like this isn't just a pat on the back – it can be a rocket booster for stock value.

Smashing through our Level 2 TP

Our Take:

Now, the million-dollar question: Buy or Sell?

With PBM's recent approval, we see not just a stock, but a story of innovation and potential. This catalyst isn't just a temporary bump; it’s the kind of news that gets investors' hearts racing. With a strong entry point and significant room for growth, we’re flagging this as a Buy - but be wary that it’s already hit two of our profit levels.

This is where Mr. M's expertise shines, finding those hidden gems that could potentially skyrocket. And hey, if you're tired of hearing about these plays after the fact, maybe it’s time to join our community. Follow our signals and get real-time insights.

👾 Crypto Catalyst

Our New SSV Spot Play

The Play

We're diving back into the $SSV pool, and, it's looking more tempting than a double espresso on a Monday morning.

Here's the deal: Sherlock has laid out a triple-threat entry strategy for $SSV.

  • Entry 1 kicks off at $38.98,

  • Entry 2 drops a bit more to $35.11,

  • And Entry 3 is set at $31.33.

The daily close is lookin’ good!

Our stop-loss? A 1D close below $28.17. The final target? A whopping $120.

Remember our first $SSV trade in January? A neat 12% move that had us breaking even. Well, folks, this time we're aiming higher, and the charts are whispering sweet nothings about a new support level.

The Catalyst

Here's where the magic happens. The $SSV SPOT has been dancing around its all-time high, flirting with new levels and playing hard to get. But recently, it did a full tango above the ATH, making it its new support.

Why does this matter? Because it's not just any dance. It's a dance backed by solid confluences, including our favorite technical indicators like the 1D Order Block and Fibonacci levels. These aren't just fancy terms; they're the bread and butter of smart trading, signaling strength and momentum.

Our Take:

So, why are we bullish on $SSV? Simple. It's not just about reclaiming a new level as support; it's about the confidence in the market's momentum. The technical setup is sweeter than a slice of apple pie, with all indicators pointing towards a strong bullish trend.

And let's not forget, trading alone is like drinking decaf – it gets the job done, but where's the fun? If you want to see these signals in real time, check out our exclusive Discord community 👇️ 

✍ TL;DR

  • Psyence Biomed's ($PBM) Trading Opportunity

    • Entry Point: $1.65, targeting a rise above $2.

    • Recent Gain: Achieved $1.75, a +6% increase.

    • Catalyst: Approval from Australian Health Research Ethics Committee for a Phase IIb study on nature-derived psilocybin.

    • Our Take: Strong buy due to innovation potential and market movement, backed by Mr. M's expertise.

  • $SSV Spot Play

    • Entry Strategy: Three-tiered, starting at $38.98, down to $31.33.

    • Stop-Loss: Below $28.17.

    • Final Target: $120.

    • Catalyst: Surpassing all-time high, establishing new support level.

    • Our Take: Bullish due to strong market momentum and technical indicators suggesting a robust bullish trend.

Stay ahead, stay informed, and most importantly, stay profitable.

‘til next time,

TradingLab